Drug Trial Radar · NCT06683651
A Study in Chinese Patients With Acquired Blepharoptosis
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Oct 22, 2024
Primary completion
Jun 2026
Study completion Jun 2026
Sponsor
- Lead sponsor
- Santen Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis. At present, there are no medicines for the treatment of acquired blepharoptosis in China. Therefore, to evaluate the efficacy and safety of 0.1% STN1013800 ophthalmic solution, Vehicle (Placebo) are designed. For the screening period, 3-7 days were set to confirm the subjects and judge their qualification. Dosage and administration were based on prior clinical trial results approved at 0.1% once daily for 42 days treatment.
Conditions
- Blepharoptosis
Interventions
STN1013800 ophthalmic solutionDrug
Investigational Product: 0.1% STN1013800 ophthalmic solution
STN1013800 ophthalmic solution Liquid Base, without STN1013800Drug
Placebo control: STN1013800 ophthalmic solution Liquid Base, without STN1013800
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from Baseline in the STN1013800 group versus the Vehicle (Placebo) groupTime frame: Day 1 Hour 6 (Visit 2); Day 14 Hour 2 (Visit 3)
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Beijing Luhe Hospital, Capital Medical University
Beijing, China · Recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Beijing Chaoyang Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong
Shantou, Guangdong, China · Recruiting
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
The first affiliated hospital of Zhengzhou University
Zhengzhou, He'nan, China · Recruiting
The 2nd Affiliated Hospital of Harbin Medical University
Ha’erbin, Helongjiang, China · Recruiting
Wuhan Aier Eye Hospital
Wuhan, Hubei, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
Nanjing First Hospital
Nanjing, Jiangsu, China · Recruiting
The second norman bethune hospital of Jilin University
Changchun, Jilin, China · Recruiting
Dalian No.3 Peple's Hospital
Dali, Liaoning, China · Recruiting
The 4TH People's Hospital of Shenyang
Shenyang, Liaoning, China · Recruiting
The affiliated People's Hospital of Ningbo
Zhenjiang, Ningbo, China · Recruiting
Shandong Eye Hospital
Jinan, Shandong, China · Recruiting
Eye & Ent Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Eye Hospital
Taiyuan, Shanxi, China · Recruiting
Panzhihua Hospital of Integrated Chinese and Western Medicine
Panzhihua, Sichuan, China · Recruiting
Tianjin Eye Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Eye Hospital, Wenzhou Medical University / Zhejiang Eye Hospital
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.